Rosetta Genomics Ltd (ROSG)-Product Pipeline Analysis, 2017 Update

Rosetta Genomics Ltd (ROSG)-Product Pipeline Analysis, 2017 Update


  • Products Id :- GDME15960PD
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments

The report analyzes all pipeline products in development for the company Rosetta Genomics Ltd

The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)

The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date

The report provides detailed description of products in development, technical specification and functions

The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape

Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio

To formulate effective Research & Development strategies

Develop market-entry and market expansion strategies

Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc

Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Rosetta Genomics Ltd Company Overview 5

Rosetta Genomics Ltd Company Snapshot 5

Rosetta Genomics Ltd Pipeline Products and Ongoing Clinical Trials Overview 5

Rosetta Genomics Ltd-Pipeline Analysis Overview 8

Rosetta Genomics Ltd-Key Facts 8

Rosetta Genomics Ltd-Major Products and Services 9

Rosetta Genomics Ltd Pipeline Products by Development Stage 10

Rosetta Genomics Ltd Pipeline Products Overview 12

Bladder Cancer Prognostic Assay 12

Bladder Cancer Prognostic Assay Product Overview 12

Body Fluids-Based Diagnostic Test-Cancer 13

Body Fluids-Based Diagnostic Test-Cancer Product Overview 13

microRNA Test-Alzheimer's Disease 14

microRNA Test-Alzheimer's Disease Product Overview 14

microRNA Test-Bladder Cancer Risk Stratification 15

microRNA Test-Bladder Cancer Risk Stratification Product Overview 15

microRNA Test-Endometrial Cancer Stratification 16

microRNA Test-Endometrial Cancer Stratification Product Overview 16

microRNA Test-Gastric Cancer Recurrence 17

microRNA Test-Gastric Cancer Recurrence Product Overview 17

microRNA Test-Heart Failure 18

microRNA Test-Heart Failure Product Overview 18

microRNA Test-Ovarian Cancer 19

microRNA Test-Ovarian Cancer Product Overview 19

microRNA Test-Preeclampsia 20

microRNA Test-Preeclampsia Product Overview 20

microRNA-Based Assay-Chronic Allograft Dysfunction 21

microRNA-Based Assay-Chronic Allograft Dysfunction Product Overview 21

microRNA-Based Assay-Neuromuscular Diseases 22

microRNA-Based Assay-Neuromuscular Diseases Product Overview 22

microRNA-Based Assay-Neuromuscular Dystrophies 23

microRNA-Based Assay-Neuromuscular Dystrophies Product Overview 23

microRNA-Based Diagnostic Test-Melanoma 24

microRNA-Based Diagnostic Test-Melanoma Product Overview 24

miRscreen Test-Colon Cancer 25

miRscreen Test-Colon Cancer Product Overview 25

Prelude DCIS-Breast Cancer 26

Prelude DCIS-Breast Cancer Product Overview 26

ROS1 Lung Cancer Biomarker Assay 27

ROS1 Lung Cancer Biomarker Assay Product Overview 27

RosettaGX Reveal-Second Version 28

RosettaGX Reveal-Second Version Product Overview 28

Rosetta Genomics Ltd-Key Competitors 29

Rosetta Genomics Ltd-Key Employees 30

Rosetta Genomics Ltd-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 32

Rosetta Genomics Ltd, Recent Developments 32

Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 32

May 05, 2017: Rosetta Genomics Expands International Access for RosettaGX Reveal through Agreement with Cytolog Laboratories in Brazil 32

May 02, 2017: Rosetta Genomics to Increase Investment in RosettaGX Reveal and Explore Strategic Alternatives for the PersonalizeDx Business 33

May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan 33

Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 34

Mar 20, 2017: Rosetta Genomics Fortifies Patent Protection For Its Unique RosettaGX Reveal Assay 36

Feb 07, 2017: Rosetta Genomics Reports Preliminary RosettaGX Reveal Financial Results for the 2016 Fourth Quarter and Year 36

Feb 06, 2017: Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGx RevealTM microRNAs 37

Oct 27, 2016: Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology 38

Oct 24, 2016: RosettaGX Reveal Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology 38

Appendix 39

Methodology 39

About GlobalData 41

Contact Us 41

Disclaimer 41

List of Figures

Rosetta Genomics Ltd Pipeline Products by Equipment Type 6

Rosetta Genomics Ltd Pipeline Products by Development Stage 10

List of Tables

Rosetta Genomics Ltd Pipeline Products and Ongoing Clinical Trials Overview 5

Rosetta Genomics Ltd Pipeline Products by Equipment Type 6

Rosetta Genomics Ltd Pipeline Products by Indication 7

Rosetta Genomics Ltd, Key Facts 8

Rosetta Genomics Ltd, Major Products and Services 9

Rosetta Genomics Ltd Number of Pipeline Products by Development Stage 10

Rosetta Genomics Ltd Pipeline Products Summary by Development Stage 11

Bladder Cancer Prognostic Assay-Product Status 12

Bladder Cancer Prognostic Assay-Product Description 12

Body Fluids-Based Diagnostic Test-Cancer-Product Status 13

Body Fluids-Based Diagnostic Test-Cancer-Product Description 13

microRNA Test-Alzheimer's Disease-Product Status 14

microRNA Test-Alzheimer's Disease-Product Description 14

microRNA Test-Bladder Cancer Risk Stratification-Product Status 15

microRNA Test-Bladder Cancer Risk Stratification-Product Description 15

microRNA Test-Endometrial Cancer Stratification-Product Status 16

microRNA Test-Endometrial Cancer Stratification-Product Description 16

microRNA Test-Gastric Cancer Recurrence-Product Status 17

microRNA Test-Gastric Cancer Recurrence-Product Description 17

microRNA Test-Heart Failure-Product Status 18

microRNA Test-Heart Failure-Product Description 18

microRNA Test-Ovarian Cancer-Product Status 19

microRNA Test-Ovarian Cancer-Product Description 19

microRNA Test-Preeclampsia-Product Status 20

microRNA Test-Preeclampsia-Product Description 20

microRNA-Based Assay-Chronic Allograft Dysfunction-Product Status 21

microRNA-Based Assay-Chronic Allograft Dysfunction-Product Description 21

microRNA-Based Assay-Neuromuscular Diseases-Product Status 22

microRNA-Based Assay-Neuromuscular Diseases-Product Description 22

microRNA-Based Assay-Neuromuscular Dystrophies-Product Status 23

microRNA-Based Assay-Neuromuscular Dystrophies-Product Description 23

microRNA-Based Diagnostic Test-Melanoma-Product Status 24

microRNA-Based Diagnostic Test-Melanoma-Product Description 24

miRscreen Test-Colon Cancer-Product Status 25

miRscreen Test-Colon Cancer-Product Description 25

Prelude DCIS-Breast Cancer-Product Status 26

Prelude DCIS-Breast Cancer-Product Description 26

ROS1 Lung Cancer Biomarker Assay-Product Status 27

ROS1 Lung Cancer Biomarker Assay-Product Description 27

RosettaGX Reveal-Second Version-Product Status 28

RosettaGX Reveal-Second Version-Product Description 28

Rosetta Genomics Ltd, Key Employees 30

Rosetta Genomics Ltd, Other Locations 31

Rosetta Genomics Ltd, Subsidiaries 31

Glossary 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Rosetta Genomics Ltd, Product, Pipeline, Product Pipeline, Key Pipeline, Products by Equipment Type, Equipment Type, Therapy Area, Products by Therapy Area, Development Stage, Products by Development Stage, Milestone, Products by Milestone, Major Products, Brands, No of Products, Device Class, Market, Territory, Product Name, Therapy Name, Trial Name, Trial, Indication, Summary, Event Type, Clinical Trial, MileStone, Product Status, Product Description, Description, Patent, Patent Details, Competitors, Key Employees, Subsidiaries, Locations, News, Events, Developments, medical devices, business description, company facts, trial phase, approval, estimated, technology, product patent details, phase, trial status, trial objective, trial design, trial site, business strategies, trends, pipeline and technology, sales strategies

select a license
Single User License
USD 750 INR 55335
Site License
USD 1500 INR 110670
Corporate User License
USD 2250 INR 166005

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com